Samsung Biologics Receives 2022 CMO Leadership Award in All Six Categories


Now in its 11th year, the CMO Leadership Awards provide accurate and trusted customer feedback to help select a reputable partner for development and manufacturing needs within the biopharmaceutical and pharmaceutical industry. Since 2013, Samsung Biologics has been honored with the CMO Leadership Awards for nine consecutive years.

“We are extremely proud to receive this distinction in all six performance categories, especially at this pivotal moment in healthcare when it is more crucial than ever to successfully deliver medicines to our customers and save the lives of patients” , said John Rim, President and CEO of Samsung Biologics. “This recognition reminds us of our responsibility as a trusted CDMO partner to our customers and to respond quickly to changing industry needs.”

“For nearly a decade, these awards have proven to be most meaningful to biopharmaceutical organizations striving to achieve optimal results from their outsourcing activities,” said Louis Garguilo, editor and conference chair of Outsourced Pharma. “Our research arm, Industry Standard Research (ISR), which only interviews drug sponsors who have recently worked with specific CDMOs, guarantees the validity of these results. Our winners will be your outsourcing champions.”

Samsung Biologics demonstrated strong operational performance and business agility in 2021 with all Plants 1, 2 and 3 in stable operation. Plant 4 will begin partial operations in the fourth quarter of this year with full completion expected by the middle of next year, and the company will also begin construction of Plant 5 by 2022 where it will offer product services multimodal in addition to the mRNA vaccine drug substance (DS) manufacturing suite is expected to be ready for cGMP operations early this year.

About Samsung Biologics Co., Ltd.

Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering industry-leading services in contract development, manufacturing and bioanalytical testing. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is the only one capable of supporting the development and manufacturing of biologics every step of the way while meeting the needs evolving biopharmaceuticals. companies around the world. For more information, visit

About the CMO Leadership Awards

Now in its 11th year, the Outsourced Pharma and Life Science Leader’s CMO Leadership Awards provide readers with accurate and reliable customer feedback to help them choose a reputable partner for their development and manufacturing needs. For the 2022 CMO Leadership Awards, Industry Standard Research (ISR) determined the winners by evaluating more than 86 contractors. These CMOs were evaluated by 23 performance measures in ISR’s annual Contract Manufacturing Quality Benchmarking Survey. For more information on awards, visit the awards website.

Contact Samsung Biologics
Claire Kim
Senior Director, Global Marketing Communications
[email protected]

SOURCESamsung Biologics


Comments are closed.